Boston Scientific completes Preventice buy, divests BTG Pharmaceutical business

Boston Scientific (NYSE:BSX) announced that it completed its acquisition of Preventice Solutions that could be worth up to $1.225 billion.

The transaction includes a cash payment of $925 million upfront with up to an additional $300 million in potential commercial milestone payments available. Accounting for the company’s approximately 22% equity stake in Preventice prior to the acquisition, the deal will be worth approximately $720 million upfront and $230 million in potential milestone payments, according to a news release.

Marlborough, Mass.-based Boston Scientific announced the planned acquisition of Minneapolis-based Preventice on Jan. 21, 2020.

Preventice designs mobile health solutions and remote monitoring offerings for patients with cardiac arrhythmias. Among its products are wearables, including the PatientCare platform and BodyGuardian family of monitors.

BodyGuardian monitors use a fully-integrated, cloud-based platform for clini…

Read more
  • 0